Validating Injury to the Renal Transplant Using Urinary Signatures in Children

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

5 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The Validating Injury to the Renal Transplant Using Urinary Signatures in Children (VIRTUUS) observational study includes three specific aims:

  • To validate highly sensitive and specific adult urinary mRNA signatures to assess allograft injury in pediatric recipients
  • To evaluate the clinical efficacy of urine metabolite profiling to identify and characterize albumin-to-creatinine ratio (ACR) in pediatric recipients
  • To validate the sensitivity and specificity of a combined adult renal allograft urinary mRNA and metabolite signature in pediatric recipients to characterize ACR.

These aims will be achieved through the collaborative effort of key pediatric kidney transplant programs across the United States and Canada, supported by two outstanding labs at Cornell and Stanford. This study’s results will advance the ability to identify and characterize early allograft injury in pediatric renal allograft recipients through non-invasive immune surveillance. By doing so, researchers will create opportunities to better inform clinical decision-making, improving practice paradigms to promote positive long-term graft outcomes.

Additionally, VIRTUUS investigators will create and maintain a DNA database abstracted from saliva, blood, and tissue samples collected throughout the study. This database will be used for ancillary studies.

Research Project Highlights

  • Urological and Renal disease Engaging Adolescents in Adherence Collaborative Trial (U-REAACT): A randomized controlled trial designed to improve treatment adherence for adolescents and young adults with kidney transplants and those with spina bifida, who must interrupt their daily lives frequently to take medicines or self-catheterize. This study aims to test an innovative strategy to help them improve their treatment adherence, using mobile phone-based technologies with text reminders, tailored feedback, education, and financial incentives.